Cem Elbi

2.8k citations

38 papers · 2.2k indexed · h-index 23

Impact in

Molecular Biology top 5%
- Genomics and Chromatin Dynamics
- RNA Research and Splicing
- Epigenetics and DNA Methylation
- Fibroblast Growth Factor Research
Biophysics top 5%

Papers in

Biotechnology 6
- Cancer Research and Treatments 6
Biophysics 3

Co-authors: Gordon L. Hager Fahri Saatcioglu Tom Misteli David T. Brown Paola Scaffidi Jaromı́ra Večeřová Robert D. Phair Keiko Ozato
Journals: Cancer Research (5 papers)Molecular and Cellular Biology (4 papers)Journal of Biological Chemistry (3 papers)Oncogene (3 papers)Journal of Thoracic Oncology (2 papers)
Partner nations: United States Germany Australia

In The Last Decade

Cem Elbi

38 papers receiving 2.2k citations

Peers

Countries citing papers authored by Cem Elbi

Since Specialization

Citations

This map shows the geographic impact of Cem Elbi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cem Elbi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cem Elbi more than expected).

Fields of papers citing papers by Cem Elbi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cem Elbi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cem Elbi. The network helps show where Cem Elbi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Cem Elbi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Cem Elbi Line = papers co-authored together Cem Elbi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma Scientific Reports ·Charles S. Cleeland, Karen Keating, Brian J. Cuffel, Cem Elbi, Jonathan Siegel, Christoph Gerlinger, Tara Symonds, Jeff A. Sloan, Amylou C. Dueck, Л. Р. Прус, Xin Shelley Wang, Loretta A. Williams, Tito R. Mendoza	2024	2
2	Targeting mesothelin in cancer Molecular Therapy — Oncolytics ·Cem Elbi	2023	1
3	Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study International Journal of Gynecological Cancer ·Alessandro D. Santin, Ignace Vergote, Antonio González-Martı́n, Kathleen N. Moore, Ana Oaknin, Ignacio Romero, Sami Diab, Larry J. Copeland, Bradley J. Monk, Robert L. Coleman, Thomas J. Herzog, Jonathan Siegel, L. S. Hurtado Paredes, Andreas Schlicker, T. Listovsky, Karl Köchert, Annette O. Walter, Barrett H. Childs, Cem Elbi, Iurie Bulat	2022	28
4	Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM) Journal of Patient-Reported Outcomes ·Tito R. Mendoza, Loretta A. Williams, Karen Keating, Jonathan Siegel, Cem Elbi, Anna K. Nowak, Raffit Hassan, Brian J. Cuffel, Charles S. Cleeland	2019	6
5	Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies Annals of Oncology ·Alex A. Adjei, Annette O. Walter, Lisa Cupit, Jonathan Siegel, 孙劲松, Barrett H. Childs, Cem Elbi	2017	2
6	P2.06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma Journal of Thoracic Oncology ·Raffit Hassan, Ross Jennens, Jan P. van Meerbeeck, John Nemunaitis, George R. Blumenschein, Dean A. Fennell, Hedy L. Kindler, Silvia Novello, Annette O. Walter, Danila Serpico, Jonathan Siegel, 孙劲松, Barrett H. Childs, Cem Elbi	2017	1
7	Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status Cancer Cell International ·Sybil M. Genther Williams, Hans Zijlstra, Paula B. Andrade, Brian Dolinski, Cem Elbi, Rónán C. O’Hagan, Carlo Toniatti	2015	31
8	FGFR2 -Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival Cancer Research ·Kaiko Kunii, Lenora J. Davis, Julie Gorenstein, Harold Hatch, Masakazu Yashiro, Alessandra Di Bacco, Cem Elbi, Bart Lutterbach	2008	230
9	Chromatin Remodeling Complexes Interact Dynamically with a Glucocorticoid Receptor–regulated Promoter Molecular Biology of the Cell ·Thomas A. Johnson, Cem Elbi, Bhavin S. Parekh, Gordon L. Hager, Sam John	2008	71
10	Nonsecreted Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Can Induce Apoptosis in Human Prostate Cancer Cells by IGF-independent Mechanisms without Being Concentrated in the Nucleus Journal of Biological Chemistry ·Nisan Bhattacharyya, Klaus Pechhold, Hannah R. Malinosky, Giovanna Zappalà, Cem Elbi, Bruce M. Raaka, Małgorzata Wiench, Hong Jiang, Matthew M. Rechler	2006	65
11	Chromatin dynamics and the evolution of alternate promoter states Chromosome Research ·Gordon L. Hager, Cem Elbi, Thomas A. Johnson, Ty C. Voss, Akhilesh K. Nagaich, R. Louis Schiltz, Yi Qiu, Sam John	2006	54
12	Ligand-Specific Dynamics of the Androgen Receptor at Its Response Element in Living Cells Molecular and Cellular Biology ·Tove Irene Klokk, 悟甲斐, Cem Elbi, Akhilesh K. Nagaich, P.O. Box Joseph R. Zoeller and Theresa Barnette Eastman Chemical Company, Thomas Slagsvold, Ching‐Yi Chang, Gordon L. Hager, Fahri Saatcioglu	2006	95
13	Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins Oncogene ·Marie Knockaert, Marc Blondel, Joseph W. Petersen, Gabriela Fernanda Serrano-Ortega, Cem Elbi, Gordon L. Hager, Scott R. Nagy, Dalho Han, Michael S. Denison, Martine Ffrench, Shuxin Xie, Prokopios Magiatis, Baxodir Аbdullayev, Paul Greengard, Isaías Juárez-Barojas, Laurent Meijer	2004	79
14	Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage Oncogene ·Kathleen M. Dohoney, Claire Guillerm, Craig C. Whiteford, Cem Elbi, Paul F. Lambert, Gordon L. Hager, John Brady	2004	59
15	Global Nature of Dynamic Protein-Chromatin Interactions In Vivo: Three-Dimensional Genome Scanning and Dynamic Interaction Networks of Chromatin Proteins Molecular and Cellular Biology ·Robert D. Phair, Paola Scaffidi, Cem Elbi, Jaromı́ra Večeřová, Anup Dey, Keiko Ozato, David T. Brown, Gordon L. Hager, Michael Bustin, Tom Misteli	2004	370
16	Subnuclear Trafficking and Gene Targeting by Steroid Receptors Annals of the New York Academy of Sciences ·Akhilesh K. Nagaich, Geetha Vani Rayasam, Susan Perkins, Matthias Becker, Yi Qiu, Thomas A. Johnson, Cem Elbi, Terace M. Fletcher, Sam John, Gordon L. Hager	2004	39
17	Glucocorticoid-like effects of antihepatocarcinogen Rotenone are mediated via enhanced serum corticosterone levels: Molecular Fitting and Receptor Activation Studies. Journal of Carcinogenesis ·Jihan Youssef, Cem Elbi, Barbour S. Warren, David M. Yourtee, Carol Hahn Johnson, Agostino Molteni, Michael L. Cunningham, Mostafa Z. Badr	2003	5
18	Recruitment of Dioxin Receptor to Active Transcription Sites Molecular Biology of the Cell ·Cem Elbi, Tom Misteli, Gordon L. Hager	2002	65
19	Molecular Cloning and Characterization of STAMP1, a Highly Prostate-specific Six Transmembrane Protein that Is Overexpressed in Prostate Cancer Journal of Biological Chemistry ·Kemal Korkmaz, Cem Elbi, Ceren Gönen Korkmaz, Massimo Loda, Gordon L. Hager, Fahri Saatcioglu	2002	80
20	Protein dynamics in the nuclear compartment Current Opinion in Genetics & Development ·Gordon L. Hager, Cem Elbi, Matthias Becker	2002	62

About Cem Elbi

Cem Elbi is a scholar working on Biotechnology, Biophysics, Oncology, Reproductive Medicine and Molecular Biology, having authored 38 papers that have together received 2.2k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (8 papers), Occupational and environmental lung diseases (6 papers), Cancer Research and Treatments (6 papers), Genomics and Chromatin Dynamics (5 papers), Mass Spectrometry Techniques and Applications (3 papers), Neuroendocrine Tumor Research Advances (3 papers), Ovarian cancer diagnosis and treatment (3 papers) and Heat shock proteins research (3 papers). The work is most often cited by research in Molecular Biology (1.4k citations), Biophysics (97 citations), Oncology (462 citations), Cancer Research (219 citations) and Genetics (397 citations). Cem Elbi has collaborated with scholars based in United States, Germany and Australia. Frequent co-authors include Gordon L. Hager, Fahri Saatcioglu, Tom Misteli, David T. Brown, Paola Scaffidi, Jaromı́ra Večeřová, Robert D. Phair, Keiko Ozato, Anup Dey and Michael Bustin. Their work appears in journals such as Cancer Research, Molecular and Cellular Biology, Journal of Biological Chemistry, Oncogene and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact